Literature DB >> 21922298

Matrix metalloproteinase-9 is consistently expressed in Hodgkin/Reed-Sternberg cells and has no impact on survival in patients with Epstein-Barr virus (EBV)-related and non-related Hodgkin lymphoma in Brazil.

Eni M Souza1, Otávio C G Baiocchi, Maria A Zanichelli, Antonio C Alves, Marianne G Assis, Joyce M K Silva, Cristine Dobo, José S R Oliveira.   

Abstract

Clinical and histological features of classical Hodgkin lymphoma (cHL) are primarily due to the effects of cytokines and enzymes produced by Hodgkin/Reed-Sternberg (HRS) cells and their surrounding inflammatory cells. In EBV-related cancers, the expression of viral latent membrane protein 1 correlates with an increased MMP9 expression. In this study, we evaluated the prognostic relevance of MMP9 expression and EBV status in HRS cells in patients with cHL in Brazil. We selected 97 patients with cHL for EBV and MMP9 detection. EBV was detected in 52.5%, and MMP9 expression positivity was found in 87.6%. Of all cases, there was no correlation between MMP9 expression and EBV status. Response to treatment and relapse rate was independent of MMP9 expression and EBV status. MMP9 positivity did not influence overall survival and event-free survival. The consistent and increased intensity of MMP9 expression in HRS cells make this enzyme a potential target for therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21922298     DOI: 10.1007/s12032-011-0063-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  18 in total

1.  Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.

Authors:  K M Kaye; K M Izumi; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

2.  Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2.

Authors:  H Takeshita; T Yoshizaki; W E Miller; H Sato; M Furukawa; J S Pagano; N Raab-Traub
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

3.  Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma.

Authors:  T Horikawa; T Yoshizaki; T S Sheen; S Y Lee; M Furukawa
Journal:  Cancer       Date:  2000-08-15       Impact factor: 6.860

4.  Expression of the matrix metalloproteinase 9 in Hodgkin's disease is independent of EBV status.

Authors:  J R Flavell; K R Baumforth; D M Williams; M Lukesova; J Madarova; V Noskova; J Prochazkova; D Lowe; Z Kolar; P G Murray; P N Nelson
Journal:  Mol Pathol       Date:  2000-06

5.  Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

Authors:  David B Duggan; Gina R Petroni; Jeffrey L Johnson; John H Glick; Richard I Fisher; Joseph M Connors; George P Canellos; Bruce A Peterson
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

6.  Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study.

Authors:  Ruth F Jarrett; Gail L Stark; Jo White; Brian Angus; Freda E Alexander; Andrew S Krajewski; June Freeland; G Malcolm Taylor; Penelope R A Taylor
Journal:  Blood       Date:  2005-06-07       Impact factor: 22.113

Review 7.  Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets.

Authors:  Pia Vihinen; Veli-Matti Kähäri
Journal:  Int J Cancer       Date:  2002-05-10       Impact factor: 7.396

8.  Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma.

Authors:  Koh-ichi Sakata; Masaaki Satoh; Masanori Someya; Hiroko Asanuma; Hisayasu Nagakura; Atushi Oouchi; Kensei Nakata; Katsuhisa Kogawa; Kazumitsu Koito; Masato Hareyama; Tetsuo Himi
Journal:  Cancer       Date:  2004-01-15       Impact factor: 6.860

9.  Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease.

Authors:  P G Murray; L S Young; M Rowe; J Crocker
Journal:  J Pathol       Date:  1992-01       Impact factor: 7.996

Review 10.  MMP9 potentiates pulmonary metastasis formation.

Authors:  Léon C L van Kempen; Lisa M Coussens
Journal:  Cancer Cell       Date:  2002-10       Impact factor: 31.743

View more
  1 in total

1.  Matrix metalloproteinase-9 expression by Hodgkin-Reed-Sternberg cells is associated with reduced overall survival in young adult patients with classical Hodgkin lymphoma.

Authors:  Antonio Hugo Campos; Jose Vassallo; Fernando Augusto Soares
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.